Отправить статью по E-mail Целесообразность продолжения терапии бевацизумабом после прогрессирования у больных метастатическим колоректальным раком
- Авторы: Доброва НВ1, Гуторов СЛ1, Черноглазова ЕВ1
-
Учреждения:
- ФГБУ РОНЦ им. Н.Н.Блохина РАМН
- Выпуск: Том 14, № 4 (2012)
- Страницы: 32-35
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/29524
- ID: 29524
Цитировать
Полный текст
Аннотация
Об авторах
Н В Доброва
ФГБУ РОНЦ им. Н.Н.Блохина РАМНФГБУ РОНЦ им. Н.Н.Блохина РАМН
С Л Гуторов
ФГБУ РОНЦ им. Н.Н.Блохина РАМНФГБУ РОНЦ им. Н.Н.Блохина РАМН
Е В Черноглазова
ФГБУ РОНЦ им. Н.Н.Блохина РАМНФГБУ РОНЦ им. Н.Н.Блохина РАМН
Список литературы
- Miles D, Harbeck N, Escudier B et al. Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials. J Clin Oncol 2011; 29 (1): 83.
- Leonard B. Zaltz, Stephen Clarke et al. Bevacizumab in combination with Oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studies. J Clin Oncol 2008; 26 (12).
- Kozloff M, Ulcickas Yood M et al. Clinical Outcomes Associated with Bevacizumab- Containing Treatment of Metastatic Colorectal Cancer: The BRITE Observation Cohort Study. Oncologist 2009; 14: 862-70.
- Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-34.
- Bendell JC, Bekaii-Saab TS, Cohn AL et al. Treatment Patterns and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, Bevacizumab Observational Cohort Study. Oncologist 2012. Sep 26. [Epub ahead of print].
- Cohn AL, Bekaii-Saab T, Bendell JC et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). Abstr. 3596.
- Masi G, Loupakis F, Salvatore L et al. A randomized study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). Vienna 2012 Congress, Vienna 2012 App.
- Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after fi rst progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Published Online November 16, 2012. http://dx.doi.org/10.1016/S1470-2045(12)70477-1
